7 unknown. 7 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 7 |
| Phase 2 | 4 | Unknown 4 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| New Antiviral Drugs for Treatment of COVID-19 Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : - COVID, Drug Effect | Phase 3 | Unknown | Mansoura University | 100 | 2020-10-01 | 2020-09-03 |
| P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 P2Et (Caesalpinia spinosa extract), Placebo - COVID, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | Hospital Universitario San Ignacio | 100 | 2020-09-30 | 2021-08-10 |
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients Systemic indirect endovenous ozone therapy - COVID | Phase 3 | Unknown | Javier Hidalgo Tallón | 50 | 2020-07-01 | 2020-06-23 |
| High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Enoxaparin - COVID, Pneumonia, Viral | Phase 3 | Unknown | Azienda Ospedaliero-Universitaria di Modena | 300 | 2020-06-01 | 2020-05-29 |
| Ivermectin in Treatment of COVID-19 Ivermectin - COVID | Phase 2 / Phase 3 | Unknown | Zagazig University | 100 | 2020-05-31 | 2020-06-24 |
| Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome Convalescent plasma, Standard of care - COVID, Acute Respiratory Distress Syndrome | Phase 2 / Phase 3 | Unknown | Universitas Indonesia | 60 | 2020-05-18 | 2020-08-18 |
COVID-19 (4) · Coronavirus Infections (1) · Hemostatic Disorders (1) · Pneumonia (1) · Pneumonia, Viral (1) · Respiratory Distress Syndrome (1)
Lung Diseases (5) · Respiratory Tract Diseases (5) · Coronaviridae Infections (4) · Infections (4) · Nidovirales Infections (4) · RNA Virus Infections (4) · Respiratory Tract Infections (4) · Virus Diseases (4) · Coronavirus Infections (3) · Pneumonia (3) · Pneumonia, Viral (3) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1)
Ivermectin (2) · Enoxaparin (1) · Ribavirin (1) · Sofosbuvir (1) · Standard of Care (1) · daclatasvir (1)
Azienda Ospedaliero-Universitaria di Modena (1) · Hospital Universitario San Ignacio (1) · Javier Hidalgo Tallón (1) · Mansoura University (1) · Tanta University (1) · Universitas Indonesia (1) · Zagazig University (1)
Egypt (3) · Colombia (1) · Indonesia (1) · Italy (1) · Spain (1)
Andri MT Lubis, MD, PhD (1) · Marco Marietta, MD (1) · Marwa Salama, Consultant (1)
PMID 16287208, PMID 25108173, PMID 30531947, PMID 31978945, PMID 32251768, PMID 33502773, PMID 35244208, PMID 36160152, PMID 37794281